S

Syndax

Biopharmaceutical company developing oncology therapies

Principal Statistical Programmer

Full-TimeUpdated on 10/23/2026
No salary listed
Senior, Expert
Bachelor's
New York, NY, USA
RemoteOpen to candidates from any location; east coast locations preferred. Candidates may be located anywhere; east coast locations are preferred.
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • At least eight years of relevant experience; exceptional candidates with five or more years may be considered.
  • A bachelor's degree.
  • Experience in oncology.
  • Ability to communicate technical concepts clearly and concisely to non-technical colleagues.
  • Successfully completed several large or complex projects.
  • Ability to handle multiple projects with aggressive timelines.
  • Ability to multitask and prioritize work.
  • Excellent knowledge of SAS.
  • Familiarity with coding dictionaries, including WHO and MedDRA.
  • Expertise in industry-standard initiatives such as CDISC.
  • Knowledge of medical and statistical terminology.
  • Ability to use Windows, Word, and Excel.
Responsibilities
  • Provide expert hands-on programming support and technical expertise to develop, maintain, validate, and execute SAS programs that access, visualize, analyze, and report clinical trial data in accordance with statistical analysis plans, ICH guidelines, and applicable regulatory requirements.
  • Perform statistical programming for clinical trial data analysis on in-house and outsourced trials, commercial requests, health economics and outcomes research analyses, pooled analyses such as integrated summaries of efficacy and safety, and ad hoc analyses.
  • Support study leads and take ownership of multiple deliverables within a drug program while providing support across various drug platforms.
  • Act as an integral project team member, complementing the lead programmer as required, attending project team meetings as needed, and collaborating with vendors, biostatisticians, data managers, and other cross-functional teams.
  • Serve as a primary programmer producing tables, listings, figures, and case report form tabulations for clinical trial programs, including integrated summaries of safety and efficacy.
  • Serve as a primary programmer supporting regulatory requests, commercial requests, ad hoc analyses, biomarker analyses, and health economics and outcomes research analyses.
  • Review critical standards artifacts and processes, such as statistical analysis plans, data validation plans, and electronic case report forms, and provide constructive comments as needed.
  • Troubleshoot and perform quality reviews of complex SAS programs.
  • Follow good programming practices and adequately document programs.
  • Understand and follow FDA regulations affecting clinical trial data reporting.
  • Participate in cross-functional task forces and initiatives representing Statistical Programming as needed.
Desired Qualifications
  • Leukemia experience is preferred.

About the company

S

Syndax

View
cbWebsite

Syndax Pharmaceuticals focuses on developing therapies for cancer. Its work centers on researching, testing through clinical trials, and commercializing cancer drugs, with an emphasis on difficult-to-treat cancers such as HR+ HER2- breast cancer. The company’s lead asset is Entinostat, which is being studied in combination with Exemestane for HR+ HER2- breast cancer; results from these trials will influence its growth and market position. Syndax funds its R&D and operations through capital raises and potential licensing or partnerships, and generates revenue by selling approved medicines. Its goal is to bring new cancer treatments to patients who have limited options by advancing promising oncology therapies and securing successful regulatory approvals and partnerships to scale those therapies.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2005

Get referred to Syndax

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue hit $72.8 million, up 92%, driven by Revuforj and Niktimvo.
  • Revuforj prescriptions reached about 1,500 in 2Q26, showing accelerating physician adoption.
  • Axatilimab IPF and frontline cGVHD topline data are expected in 4Q26, creating near-term catalysts.

What critics are saying

  • Kura’s ziftomenib and J&J’s bleximenib pressure Revuforj’s KMT2Ar and NPM1 franchises.
  • July 14, 2026 added SNDX-4321 and SNDX-62122, but both remain pre-IND and years from revenue.
  • If Revuforj or Niktimvo adoption slows after 2026 readouts, Syndax loses its only durable cash engine.

What makes Syndax unique

  • Revuforj became the first FDA-approved menin inhibitor on November 15, 2024.
  • Niktimvo’s Incyte partnership co-commercializes axatilimab and splits profits without building a full sales force.
  • Syndax now owns both commercial revenue and wholly owned next-generation assets, SNDX-4321 and SNDX-62122.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

5%
pharmaphorum
Oct 13th, 2026
Syndax shares fall as lung fibrosis drug fails trial.

Syndax shares fall as lung fibrosis drug fails trial. Syndax Pharma shares lost 17% of their value pre-market after the company said it abandoned development of a drug candidate for idiopathic pulmonary fibrosis (IPF). The decision was taken after the phase 2 MAXPIRe trial of anti-CSF-1R antibody axatilimab showed the drug was unable to slow down the rate of lung function decline in IPF patients compared to placebo over 26 weeks' follow-up. "Based on the results observed, Syndax does not plan to move forward with further development of axatilimab in IPF," said the company in a statement. Syndax is partnering with Incyte on the development of axatilimab, which is already approved as a treatment for chronic graft-versus-host disease (GvHD) in the US under the Niktimvo brand name. Shares in Incyte, which licensed rights to axatilimab from Syndax in a 2021 deal worth up to $600 million, also dipped slightly after the announcement. "The MAXPIRe trial did not meet its primary endpoint, and we are disappointed by this outcome, given the promising scientific rationale in IPF," said Syndax's chief medical officer and head of R&D, Nick Botwood. While Syndax and Incyte are continuing to study Niktimvo in cGVHD, seeking to move it earlier in the treatment pathway from its current third-line or later indication, there's no overplaying the impact of the IPF decision on the drug's peak sales prospects, given that the disease affects millions of people worldwide. "Axatilimab was well tolerated, with a safety profile consistent with prior studies supporting its continued development and use in cGVHD," said Botwood. "There are multiple trials underway in cGVHD where axatilimab has shown remarkable results, and we look forward to readouts from these trials later this year and in early 2028." Those include the phase 3 AXemplify-357 trial in newly diagnosed cGVHD as a combination with corticosteroids, and a phase 2 study in the frontline setting in a dual regimen with Incyte's JAK inhibitor Jakafi (ruxolitinib). Syndax' chief executive, Michael Metzger, said that the company remains confident that Niktimvo can pass the $1 billion annual sales threshold and become a blockbuster product. Total revenues were around $152 million last year and accelerated to $115 million in the first half of 2026. The truncated potential for Niktimvo means that Syndax will rely more heavily on its other approved product, oral menin inhibitor Revuforj (revumenib), which is indicated for relapsed or refractory acute leukaemia with translocations in the KMT2A gene and is being developed for other blood cancers. The company has predicted Revuforj could become a $2 billion-a-year product. 13 October, 2026

The Armchair Trader
Sep 28th, 2026
Diaceutics accelerates growth on precision medicine demand.

Diaceutics accelerates growth on precision medicine demand. Diaceutics LON:DXRX is entering the second half of 2026 with growing momentum, after a sharp increase in recurring revenue, a stronger order book and positive free cash flow coincided with an expanded partnership with US biopharma group Syndax Pharmaceuticals. The Belfast-based diagnostic intelligence company reported first-half revenue of £17.5m, up 20% year on year and 22% at constant currency. Annual recurring revenue (ARR) was the standout, rising 79% to £29.4m, while the order book increased 38% to £43.7m. The Armchair Trader tipped Diaceutics to its members at 155p on 11 September. The shares closed at 185.86p on Friday. The quality of that growth is also improving. Net revenue retention reached 149%, meaning the existing customer base generated substantially more recurring revenue than a year earlier, while gross ARR churn fell to 6%. Gross margin increased to 85% from 83%, and adjusted EBITDA swung from £57,000 to £1.1m. For shareholders, the move into positive free cash flow is particularly significant. Diaceutics generated £0.7m of free cash flow in the first half, an improvement of £3.1m on the previous year. The company ended June with £8.1m of cash and no debt, leaving it funded to pursue its organic growth strategy. Syndax partnership puts Relay in the spotlight. The latest evidence of Diaceutics' commercial traction came last week, when it announced an expansion of its multi-year Relay partnership with Syndax. The agreement will support the commercialisation of Syndax's precision oncology medicine for acute leukaemia, helping identify eligible patients sooner and supporting more timely access to treatment. The expanded relationship builds on a partnership signed in the fourth quarter of 2025. The financial terms have not been disclosed, but the strategic significance is clearer. Relay brings together Diaceutics' diagnostic regulatory planning, testing intelligence, concordance studies, scientific engagement and physician education into a single commercialisation model. That is important because precision medicines depend on patients being identified through the right diagnostic pathway. Diaceutics aims to use its data and intelligence to show pharmaceutical companies where eligible patients may be missed and help coordinate activity between laboratories, healthcare professionals and commercial teams. Relay is already showing encouraging traction. ARR from existing Relay relationships increased from £2.6m at contract inception to £4.3m at June 30, while the company said new customers were in the final stages of contract negotiations. Bigger market gives Diaceutics room to scale. The broader opportunity could be considerably larger than Diaceutics' historical focus on precision medicine. In September, the company launched its "Precision For All" repositioning, expanding its addressable therapy universe from about 250 precision medicine therapies to more than 1,100 diagnostic-driven therapies. That gives management a much larger potential customer base while allowing it to build on the same underlying diagnostic intelligence infrastructure. Diaceutics already works with 18 of the world's top 20 pharmaceutical companies, supporting 55 customers across 103 therapeutic brands. Its Signal product also saw ARR increase 46% during the first six months of the year and is now used across 55 brands, compared with 36 a year earlier. The company is continuing to invest in its DXRX platform, proprietary data and AI-enabled analytics, while redesigning its commercial and delivery model to support scale and improve operating leverage. Importantly, management has maintained its expectations for 2026. By the end of August, delivered revenue, contracted revenue and the risk-weighted commercial pipeline represented 107% visibility against the £46.7m median analyst consensus revenue estimate for the full year, up from 91% at the end of June. What the Armchair Trader thinks. Diaceutics' latest numbers suggest the business is moving beyond being an interesting healthcare data specialist and towards becoming a more predictable, recurring-revenue software and services company. The 79% increase in ARR is the headline number, but the 149% net revenue retention and falling churn are arguably more important because they show customers are expanding their relationships rather than simply signing once and leaving. The expanded Syndax partnership provides useful evidence that Relay can turn this infrastructure into deeper, multi-year commercial relationships. The risks remain: the company is still loss-making on a statutory basis, its growth depends heavily on winning and expanding pharmaceutical contracts, and the new addressable market will need to translate into actual revenue. Even so, the combination of high gross margins, improving cash generation, no debt and substantial pipeline visibility gives Diaceutics a solid platform. If management can sustain the current level of ARR growth while converting that scale into stronger statutory profitability, shareholders could have a particularly interesting growth story on their hands. Invest with these regulated brokers. Learn with its free 'How to' Guides.

Associated Press
Aug 4th, 2026
Syndax reports $73M total revenue in 2Q26, up 92% year-over-year

Syndax Pharmaceuticals reported second quarter 2026 total revenue of $73 million, marking a 92% year-over-year increase. Revuforj (revumenib) generated net revenue of $54.7 million, up 91% year-over-year, whilst Niktimvo (axatilimab-csfr) achieved net revenue of $60.3 million, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million. The company expanded its pipeline with a novel EGFR inhibitor for non-small cell lung cancer and a next-generation menin inhibitor for myelofibrosis. Topline data from Phase 2 trials of axatilimab in idiopathic pulmonary fibrosis and frontline chronic graft-versus-host disease are expected in the fourth quarter of 2026. For the six months ended 30 June 2026, Syndax reported a net loss of $49.4 million, or $0.55 per share.

Syndax Pharmaceuticals, Inc.
Jul 14th, 2026
Syndax to highlight late-stage programs and unveil new pipeline assets at R&D Event.

Syndax to highlight late-stage programs and unveil new pipeline assets at R&D Event. July 14, 2026 - Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs - - SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF - - SNDX-62122 is the first candidate from the Company's library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas - - Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 - - R&D Event featuring three thought leaders and members of Syndax's leadership team to be held today at 8:30 a.m. ET - NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) - Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will highlight its late-stage programs and the next chapter of its R&D strategy, including new pipeline assets, during its R&D Event being held today from 8:30 a.m. to 11:00 a.m. EDT. "Today we are unveiling our new pipeline assets which reflect the continued evolution of our R&D capabilities, including our ability to leverage both external innovation and a library of internally developed next-generation menin inhibitors to expand our portfolio and create new growth opportunities," said Michael A. Metzger, Chief Executive Officer. "With a robust financial foundation, a track record of success, and multiple near-term catalysts, Syndax is positioned to deliver the next breakthroughs for patients and drive long-term value for shareholders." "Syndax has established world-class R&D capabilities and strong partnerships with leading clinicians and scientists around the world to drive innovation and develop transformative new medicines for patients," said Nick Botwood, MBBS, Head of Research & Development and Chief Medical Officer at Syndax. "Today's event will highlight our strategy to expand our leadership in menin and CSF-1R inhibition and build our pipeline with two new differentiated assets supported by compelling preclinical data and mechanistic insights. With both Revuforj and Niktimvo, we demonstrated our ability to efficiently generate clinical data that validates new therapeutic targets, a strength we look forward to showcasing again as we advance the next chapter of our R&D strategy." Guest speakers will include: * Toby M. Maher, MD, PhD, Professor of Clinical Medicine and Director of Interstitial Lung Disease, Keck Medical School of University of Southern California, will present on idiopathic pulmonary fibrosis (IPF) and the potential for axatilimab in IPF. * John D. Crispino, PhD, MBA, Director, Division of Experimental Hematology, St. Jude Children's Research Hospital, will present on the potential for menin inhibition in myelofibrosis (MF). * Michael J. Eck, MD, PhD, Professor, Department of Cancer Biology, Dana-Farber Cancer Institute and Professor, Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, will present on the development of SNDX-4321 for EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). Highlighted R&D Day Topics SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC * SNDX-4321 is an EGFR inhibitor in development for NSCLC patient populations with significant unmet needs, such as those with L858R mutations, CNS metastases, atypical activating mutations, or acquired resistance to current therapies. In contrast to ATP-site directed third and fourth generation EGFR inhibitors, SNDX-4321 is a novel allosteric inhibitor which binds at a pocket adjacent to the ATP site that is only accessible in the presence of L858R and certain other EGFR mutations. The Company expects to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and to initiate a Phase 1 trial in EGFRm NSCLC in 2027. SNDX-4321 is an externally developed molecule that the Company has an exclusive worldwide license to develop and commercialize. During the R&D Event, the Company will highlight the potential advantages of an allosteric approach in EGFRm NSCLC and the supporting preclinical data. SNDX-62122, a candidate from the Company's library of internally developed next-generation menin inhibitors, selected for development in MF * SNDX-62122 is the first candidate from a library of wholly owned next-generation menin inhibitors that the Company intends to advance into new areas. * SNDX-62122 is in development for MF, with submission of an IND and initiation of a Phase 1 trial in MF expected in 2027. During the R&D Event, the Company will highlight recently published revumenib preclinical data showing that menin is a novel dependency in proliferative megakaryocytes, major drivers of MF. The Company expects the development of SNDX-62122 to be informed and de-risked by a Phase 1/2 proof-of-principal trial of revumenib in MF that is expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027. Ongoing late-stage trials of Revuforj(R)(revumenib) and Niktimvo(TM)(axatilimab-csfr) * During the R&D event, the Company will highlight its late-stage revumenib and axatilimab programs in newly diagnosed acute leukemia and chronic GVHD, respectively, as well as the Phase 2 trial of axatilimab in IPF that is expected to readout in the fourth quarter of 2026. During the R&D event, Dr. Toby M. Maher will discuss the unmet patient needs, evolving treatment landscape, and the potential for axatilimab's mechanism in IPF. Syndax will host an R&D Event today, July 14, 2026, from 8:30 a.m. to 11:00 a.m. ET in person and via webcast. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following link: https://sndx-rdevent-2026.open-exchange.net/. For those unable to join the live webcast, a replay will be available in the Investors section of the Company's website at https://syndax.com/ after the event and will be available for a limited time. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj(R)(revumenib), an FDA-approved menin inhibitor, and Niktimvo(TM)(axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by its commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, the acceptance of Syndax and its partners' products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj's or Niktimvo's commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. Syndax Contact Sharon Klahre Syndax Pharmaceuticals, Inc. [email protected] Tel 781.684.9827

Syndax Pharmaceuticals, Inc.
Jun 18th, 2026
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes | Syndax Pharmaceuticals, Inc.

The Investor Relations website contains information about Syndax Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.